News

Merck Loses First Vioxx Lawsuit


 

A jury in Texas last month awarded $253 million to the widow of a man who died after taking Vioxx (rofecoxib). The plaintiff charged that the drug maker Merck & Co. failed to warn physicians about the danger posed by Vioxx, that the drug was improperly designed, and that the company's negligence caused the death of the plaintiff's husband, Robert Ernst. Merck executives plan to appeal the verdict on the grounds that the jury was allowed to hear testimony that was both irrelevant and not based on reliable science, the company said. "While we are disappointed with the verdict, this decision should be put in its appropriate context," Kenneth C. Frazier, Merck's senior vice president and general counsel, said in a statement. "This is the first of many trials. Each case has a different set of facts. Regardless of the outcome in this single case, the fact remains that plaintiffs have a significant legal burden in proving causation." The award included $24 million in actual damages and $229 million in punitive damages. But the punitive damages could be reduced to about $2 million, according to Merck.

Recommended Reading

Policy & Practice
MDedge Dermatology
Liability Fears May Slow Safety System Acceptance
MDedge Dermatology
New Medicare Process: Limited Appeal for Elderly?
MDedge Dermatology
Onus on Physicians to Clarify Patients' Part D Drug Benefits
MDedge Dermatology
Analysts Predict Surge in Limited Insurance Policies
MDedge Dermatology
Organizations Need HIPAA Complaint Process
MDedge Dermatology
AMA House Divided on Pay for Performance
MDedge Dermatology
Informing Low-Literacy Patients: Clarify, Simplify
MDedge Dermatology
CMS Calls for 4.3% Pay Reduction Next Year
MDedge Dermatology
Doctors Share Their Weight-Loss Strategies
MDedge Dermatology